Biotech Unusual Volume: Agios Pharmaceuticals (NASDAQ:AGIO), OHR (NASDAQ:OHRP), La Jolla (NASDAQ:LJPC), Aastrom Biosciences (NASDAQ:ASTM)

Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a research report issued to clients and investors on Monday, Analyst Ratings News reports. Agios Pharmaceuticals Inc (NASDAQ:AGIO) stock performance was 2.84% in last session and finished the day at $46.74. Traded volume was 983,271 million shares in the last session and the average volume of the stock remained 300.25 million shares. Agios Pharmaceuticals Inc (NASDAQ:AGIO) insider ownership is 0.40%.

Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) was a big mover last session, as the company saw its shares surge 22% on the day. This rally higher can be attributable to solid volume too with far more shares changing hands than in a normal session. OHR Pharmaceutical Inc (NASDAQ:OHRP) rose 10.55 percent to $19.60 yesterday on volume of 391.41 million shares. The intra-day range of the stock was $17.48 to $19.71. OHR Pharmaceutical Inc (NASDAQ:OHRP) has a market capitalization of $391.41 million.

La Jolla Pharmaceutical Co (NASDAQ:LJPC) Monday said its randomized, placebo-controlled Phase 2 trial of GCS-100 in chronic kidney disease or CKD met its primary efficacy endpoint of a statistically significant improvement in kidney function. La Jolla Pharmaceutical Company (NASDAQ:LJPC)’s stock on Mar 10, 2014 reported an increase of 11.68% to the closing price of $10.90. Its fifty two weeks range is $2.75 -$12.00. The total market capitalization recorded $48.01 million. The overall volume in the last trading session was 1,745,453 million shares. In its share capital, La Jolla Pharmaceutical Company (NASDAQ:LJPC) has 0.55 million outstanding shares.

Aastrom Biosciences, Inc. (NASDAQ:ASTM) entered into a purchase agreement (the “Purchase Agreement”), together with a registration rights agreement (the “Registration Rights Agreement”), with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which the Company has the right to sell to Lincoln Park up to $15,000,000 in shares of its common stock, no par value (“Common Stock”), subject to certain limitations. On Monday, shares of Aastrom Biosciences Inc (NASDAQ:ASTM) advanced 16.07% to close the day at $3.90. Company’s monthly performance is recorded as 14.04%. Aastrom Biosciences Inc (NASDAQ:ASTM) quarterly revenue growth is 6.85%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone